Lund — 4 February 2016 — According to the instruction for Nomination Committee in Camurus AB adopted at the extraordinary general meeting held on 15 October 2015, the Nomination Committee for the annual general meeting 2016 shall be composed of representatives of the three largest shareholders in terms of voting rights as of 31 December 2015, along with the Chairman of the Board of Directors. The composition of the Nomination Committee has now been established, and Camurus today announced that the Nomination Committee in respect of the AGM 2016 consists of the following persons who together represent approximately 67 percent of the number of shares and votes in the company based on the last known shareholder information.
- Per Sandberg, representing Sandberg Development AB
- Jan Andersson, representing Swedbank Robur Fonder
- Mikael Hanell, representing Catella Fonder
- Per Olof Wallström, Chairman of the Board
Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company’s address. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 15 March 2016, to ensure that the proposals can be considered by the Nomination Committee.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com.
For more information
Per Olof Wallström, Chairman of the Board
Tel. +46 709 42 95 20
The information in this press release is disclosed by Camurus AB in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 08.00 a.m. on 4 February 2016.